ClinicalTrialsFinder

EGFR-TKI Resistant Mutation Clinical Trials in Tianjin, Tianjin Municipality

1 recruitingTianjin, Tianjin Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734